Tekla Life Sciences Investors (HQL)

US — Financial Services Sector

Peers: THW THQ RVT BTO HQH DFP UTF ETG MYD EVT ETB NXC RNP XFLT JPI FPF FFC ETJ

Automate Your Wheel Strategy on HQL

With Tiblio's Option Bot, you can configure your own wheel strategy including HQL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol HQL
Rev/Share 0.1383
Book/Share 15.977
PB 0.7874
Debt/Equity 0.0
CurrentRatio 0.3169
ROIC -0.0041

MktCap 363214792.0
FreeCF/Share 0.0
PFCF 0.0
PE 4.2435
Debt/Assets 0.0
DivYield 0.1502
ROE 0.1894

Rating B+
Score 3
Recommendation Neutral
P/E Score 4
DCF Score 1
P/B Score 3
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

HQL: Positive Outlook Due To Increased Healthcare Spending

HQL
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Positive

I maintain my buy rating on HQL due to its attractive 14% yield, discounted valuation, and long-term healthcare growth outlook. Despite recent NAV declines and inconsistent income, HQL's performance is tied to macro conditions, not internal flaws, and should improve as the sector rebounds. HQL's diversified biotech-heavy portfolio, lack of leverage, and simple strategy offer stability and upside as healthcare spending rises.

image for news HQL: Positive Outlook Due To Increased Healthcare Spending

These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount

BCAT, BSTZ, HQL
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive

My definition of a high yield is any yield at least twice the level of the S&P 500's yield. The threshold is currently around 2.56%.

image for news These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount

HQL: Attractive Valuation, Aligned To Benefit From Aging Gen X

HQL
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Positive

HQL: Attractive Valuation, Aligned To Benefit From Aging Gen X

About Tekla Life Sciences Investors (HQL)

IPO Date 1992-05-01
Website https://www.teklacap.com/hql.html
Industry Asset Management
CEO Dr. Daniel R. Omstead M.S, Ph.D.
Employees None

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.